Skip NavigationSkip to Content
Return Return to Search Results

Marker of proliferation Ki-67 expression is associated with transforming growth factor beta 1 and can predict the prognosis of patients with hepatic B virus-related hepatocellular carcinoma

  1. Author:
    Yang, Chengkun
    Su, Hao
    Liao, Xiwen
    Han, Chuangye
    Yu, Tingdong
    Zhu, Guangzhi
    Wang, Xiangkun
    Winkler, Cheryl
    O'Brien, Stephen J
    Peng, Tao

  2. Author Address

    Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Province, China., Basic Research Laboratory, CCR, NCI, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD, USA., Laboratory of Genomic Diversity, National Cancer Institute, NIH, Frederick, MD, USA., Theodosius Dobzhansky Center for Genome Bioinformatics, St. Petersburg State University, St Petersburg, Russia., Guy Harvey Oceanographic Center, Halmos College of Natural Sciences and Oceanography, Nova Southeastern University, Fort Lauderdale, FL, USA.,
    1. Year: 2018
    2. Date: Apr 10
    3. Epub Date: 2018 04 10
  2. Journal: Cancer Management and Research
    1. 10
    2. Pages: 679-696
  4. Type of Article: Article
  5. ISSN: 1179-1322
  1. Abstract:

    Hepatocellular carcinoma (HCC) is the most frequent malignancy of the liver. Transforming growth factor beta 1 (TGFB1) and marker of proliferation Ki-67 (MKI67) regulate cell proliferation, differentiation, and growth. The association between MKI67 and TGFB1 expression and its clinical implications in HCC remain unknown. Public databases were used to analyze TGFB1 and MKI67 expression in different pathologic grades/stages and tissue types of HCC. The association between MKI67 and TGFB1 expression was explored using pathway analysis and in a HepG2 cell line treated with TGFB1. Survival analysis was performed to evaluate the prognostic value of TGFB1 and MKI67 expression in patients with hepatitis B virus (HBV)-related HCC. We identified that MKI67 expression was upregulated in liver cancer tissues. MKI67 and TGFB1 expression levels were different in various stages and tissue types of liver cancer. Furthermore, MKI67 expression was associated with TGFB1 expression in liver cancer tissues and HepG2 cells. Patients with HBV-related HCC and a higher level of MKI67 expression had a worse prognosis. Moreover, a nomogram was conducted to predict the clinical outcomes of patients with HBV-related HCC. MKI67 expression level was associated with TGFB1 expression in liver cancer tissues and a HepG2 cell line. MKI67 expression level can predict the clinical outcomes of patients with HBV-related HCC.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.2147/CMAR.S162595
  3. PMID: 29692627
  4. PMCID: PMC5901156
  5. View record in Web of Science®
  6. WOS: 000430091900001
  7. PII : cmar-10-679

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel